Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 13/20 | 0.73 |
| ▸ | LTB4R2 | Q9NPC1 | 9/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252 | 1.00 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2373 | 1.00 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL29669823 | 1.00 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2353 | 0.94 | AGTR1 (0.65) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL683543 | 0.94 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL4473044 | 0.93 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2758 | 0.93 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL8476198 | 0.93 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL24998852 | 0.92 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL21125607 | 0.92 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822259-B1 | METHOD FOR SYNTHESIZING VALSARTAN | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2025-08-27 | — | — | EP | claimed |
| CN-112638885-B | Synthesis method of valsartan | 浙江华海药业股份有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-117886767-A | Synthesis method of N-methyl substituted valsartan impurity | 珠海润都制药股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-115160247-A | Method for recycling methyl ester from valsartan mother liquor | 江苏新瑞药业有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-115160246-A | Process for recovering valsartan from valsartan mother liquor | 江苏新瑞药业有限公司 | 2022-10-11 | — | — | CN | claimed |
| US-11434210-B2 | Method for synthesizing valsartan | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2022-09-06 | — | — | US | claimed |
| CN-113264891-A | Method for recovering L-valsartan from valsartan mother liquor containing D-valsartan | 珠海润都制药股份有限公司 | 2021-08-17 | — | — | CN | claimed |
| EP-3822259-A1 | METHOD FOR SYNTHESIZING VALSARTAN | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2021-05-19 | — | — | EP | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-112638885-A | Synthesis method of valsartan | 浙江华海药业股份有限公司 | 2021-04-09 | — | — | CN | claimed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| WO-2020010643-A1 | METHOD FOR SYNTHESIZING VALSARTAN | 浙江华海药业股份有限公司 | 2020-01-16 | — | — | WO | claimed |
| CN-103923028-B | Preparation method of valsartan methyl ester | 青岛雪洁助剂有限公司 | 2017-05-24 | — | — | CN | claimed |
| CN-106038499-A | Valsartan dispersible tablet and preparation method thereof | 深圳市樊溪电子有限公司 | 2016-10-26 | — | — | CN | claimed |
| CN-103012301-B | Valsartan methyl ester alkali metal salt and preparation method thereof | JIANGSU SHIMEIKANG PHARMACEUTICAL CO LTD | 2015-06-17 | — | — | CN | claimed |
| CN-102649780-A | Improved process for synthesizing valsartan | GUANGDONG HEC PHARMACEUTICAL | 2012-08-29 | — | — | CN | claimed |
| CN-102321038-A | Improved valsartan preparation method | ANHUI PROVINCE HONG SHENG BIO TECHNOLOGY CO LTD | 2012-01-18 | — | — | CN | claimed |
| WO-2010091169-A2 | PREPARATION OF VALSARTAN | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-08-12 | — | — | WO | claimed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | claimed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434210-B2 | Method for synthesizing valsartan | REN, ACE, AGT | AGTR1 8/4885LTB4R2 3722/4885ABCB11 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.